Lebrun Labs LLC – Trademark Portfolio
Entity Type: 16
Lebrun Labs LLC holds 15 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 12 filings in this category. The portfolio also extends into Class 1 (Chemicals) across 3 Nice Classification classes. Currently, 3 trademarks are registered and 5 are pending. Notable registered marks include LEBRUN LABS, OPTISAFE EIT, and OPTISAFE EYE IRRITATION TEST. The owner is based in Anaheim, CA.
3301 E. Miraloma Ave., Suite 194
Anaheim, CA 92806
Showing of trademarks Trademarks
Trademark Classifications
Lebrun Labs LLC's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific and technological services; industrial analysis and research services
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does Lebrun Labs LLC have?
Lebrun Labs LLC has 15 U.S. trademarks filed with the USPTO. Of these, 3 registered, 5 pending, 7 abandoned.
What trademark classes does Lebrun Labs LLC file in?
Lebrun Labs LLC files trademarks across 3 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 1 (Chemicals), Class 5 (Pharmaceuticals). Class 42 covers scientific and technological services; industrial analysis and research services.
What are Lebrun Labs LLC's most well-known trademarks?
Lebrun Labs LLC's registered trademark portfolio includes well-known marks such as LEBRUN LABS, OPTISAFE EIT, and OPTISAFE EYE IRRITATION TEST. These are among 3 currently registered trademarks in the portfolio.
What is Lebrun Labs LLC's trademark registration success rate?
Lebrun Labs LLC has a 30% trademark registration rate, with 3 out of 10 resolved applications resulting in successful registration. Currently, 5 applications are pending review.